Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.

Hong D, Rasco D, Veeder M, Luke JJ, Chandler J, Balmanoukian A, George TJ, Munster P, Berlin JD, Gutierrez M, Mita A, Wakelee H, Samakoglu S, Guan S, Dimery I, Graef T, Borazanci E.

Oncology. 2019;97(2):102-111. doi: 10.1159/000500571. Epub 2019 Jun 21.

2.

Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia.

Cortes JE, Jonas BA, Graef T, Luan Y, Stein AS.

Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):509-515.e1. doi: 10.1016/j.clml.2019.05.008. Epub 2019 May 13.

3.

Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies.

Burger JA, Cramer P, Barr PM, Dilhuydy MS, Mato A, Byrd JC, Chang S, Graef T, Lin T, Tedeschi A.

Br J Haematol. 2019 Jul;186(1):175-180. doi: 10.1111/bjh.15784. Epub 2019 Feb 10. No abstract available.

PMID:
30739324
4.

Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis.

Brown JR, Moslehi J, Ewer MS, O'Brien SM, Ghia P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Coutre SE, Dilhuydy MS, Cramer P, Jaeger U, Dreyling M, Byrd JC, Treon S, Liu EY, Chang S, Bista A, Vempati R, Boornazian L, Valentino R, Reddy V, Mahler M, Yang H, Graef T, Burger JA.

Br J Haematol. 2019 Feb;184(4):558-569. doi: 10.1111/bjh.15690. Epub 2018 Dec 2.

5.

Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.

O'Brien S, Hillmen P, Coutre S, Barr PM, Fraser G, Tedeschi A, Burger JA, Dilhuydy MS, Hess G, Moreno C, Cramer P, Liu E, Chang S, Vermeulen J, Styles L, Howes A, James DF, Patel K, Graef T, Valentino R.

Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):648-657.e15. doi: 10.1016/j.clml.2018.06.016. Epub 2018 Jun 28.

6.

Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review.

Buske C, Sadullah S, Kastritis E, Tedeschi A, García-Sanz R, Bolkun L, Leleu X, Willenbacher W, Hájek R, Minnema MC, Cheng M, Bilotti E, Graef T, Dimopoulos MA; European Consortium for Waldenström's Macroglobulinemia.

Lancet Haematol. 2018 Jul;5(7):e299-e309. doi: 10.1016/S2352-3026(18)30087-5. Review.

PMID:
29958569
7.

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.

Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li J, Salman Z, Graef T, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia.

N Engl J Med. 2018 Jun 21;378(25):2399-2410. doi: 10.1056/NEJMoa1802917. Epub 2018 Jun 1.

8.

Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma.

Chari A, Larson S, Holkova B, Cornell RF, Gasparetto C, Karanes C, Matous JV, Niesvizky R, Valent J, Lunning M, Usmani SZ, Anderson LD Jr, Chang L, Lee Y, Pak Y, Salman Z, Graef T, Bilotti E, Chhabra S.

Leuk Lymphoma. 2018 Nov;59(11):2588-2594. doi: 10.1080/10428194.2018.1443337. Epub 2018 Apr 4.

PMID:
29616843
9.

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results.

Richardson PG, Bensinger WI, Huff CA, Costello CL, Lendvai N, Berdeja JG, Anderson LD Jr, Siegel DS, Lebovic D, Jagannath S, Laubach JP, Stockerl-Goldstein KE, Kwei L, Clow F, Elias L, Salman Z, Graef T, Bilotti E, Vij R.

Br J Haematol. 2018 Mar;180(6):821-830. doi: 10.1111/bjh.15058. Epub 2018 Feb 13.

10.

A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors.

Deutsch E, Moyal EC, Gregorc V, Zucali PA, Menard J, Soria JC, Kloos I, Hsu J, Luan Y, Liu E, Vezan R, Graef T, Rivera S.

Oncotarget. 2016 Dec 24;8(34):56199-56209. doi: 10.18632/oncotarget.14147. eCollection 2017 Aug 22.

11.

Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study.

Ribrag V, Kim WS, Bouabdallah R, Lim ST, Coiffier B, Illes A, Lemieux B, Dyer MJS, Offner F, Felloussi Z, Kloos I, Luan Y, Vezan R, Graef T, Morschhauser F.

Haematologica. 2017 May;102(5):903-909. doi: 10.3324/haematol.2016.154377. Epub 2017 Jan 25.

12.

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.

Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, Tournilhac O, Ma S, Oriol A, Heffner LT, Shustik C, García-Sanz R, Cornell RF, de Larrea CF, Castillo JJ, Granell M, Kyrtsonis MC, Leblond V, Symeonidis A, Kastritis E, Singh P, Li J, Graef T, Bilotti E, Treon S, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström's Macroglobulinemia.

Lancet Oncol. 2017 Feb;18(2):241-250. doi: 10.1016/S1470-2045(16)30632-5. Epub 2016 Dec 10.

PMID:
27956157
13.

Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia.

Vey N, Prebet T, Thalamas C, Charbonnier A, Rey J, Kloos I, Liu E, Luan Y, Vezan R, Graef T, Recher C.

Leuk Lymphoma. 2017 Aug;58(8):1880-1886. doi: 10.1080/10428194.2016.1263843. Epub 2016 Dec 2.

PMID:
27911138
14.

Extended follow-up with the Bruton's tyrosine kinase inhibitor ibrutinib in previously treated Waldenström's macroglobulinemia.

Furman RR, Luan Y, Bilotti E, Graef T.

Leuk Lymphoma. 2017 Jun;58(6):1502-1505. doi: 10.1080/10428194.2016.1247957. Epub 2016 Oct 26. No abstract available.

PMID:
27784188
15.

Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma.

Bilotti E, Vesole DH, McBride L, Schmidt L, Gao Z, Gilani M, McNeill A, Bednarz U, Richter J, Mato A, Graef T, Siegel DS.

Clin Lymphoma Myeloma Leuk. 2016 Oct;16(10):558-562. doi: 10.1016/j.clml.2016.08.001. Epub 2016 Aug 10.

PMID:
27769558
16.

VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.

Siegel DS, Dimopoulos M, Jagannath S, Goldschmidt H, Durrant S, Kaufman JL, Leleu X, Nagler A, Offner F, Graef T, Eid JE, Houp J, Gause C, Vuocolo S, Anderson KC.

Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):329-334.e1. doi: 10.1016/j.clml.2016.02.042. Epub 2016 Mar 4.

PMID:
27025160
17.

A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma.

Evens AM, Balasubramanian S, Vose JM, Harb W, Gordon LI, Langdon R, Sprague J, Sirisawad M, Mani C, Yue J, Luan Y, Horton S, Graef T, Bartlett NL.

Clin Cancer Res. 2016 Mar 1;22(5):1059-66. doi: 10.1158/1078-0432.CCR-15-0624. Epub 2015 Oct 19.

18.

Ibrutinib in previously treated Waldenström's macroglobulinemia.

Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, Argyropoulos KV, Yang G, Cao Y, Xu L, Patterson CJ, Rodig S, Zehnder JL, Aster JC, Harris NL, Kanan S, Ghobrial I, Castillo JJ, Laubach JP, Hunter ZR, Salman Z, Li J, Cheng M, Clow F, Graef T, Palomba ML, Advani RH.

N Engl J Med. 2015 Apr 9;372(15):1430-40. doi: 10.1056/NEJMoa1501548.

19.

The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.

Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A, Clow F, James DF, Graef T, Friedberg JW, Rai K, O'Brien S.

Blood. 2015 May 7;125(19):2915-22. doi: 10.1182/blood-2014-09-585869. Epub 2015 Mar 9.

20.

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.

Siegel DS, Richardson P, Dimopoulos M, Moreau P, Mitsiades C, Weber D, Houp J, Gause C, Vuocolo S, Eid J, Graef T, Anderson KC.

Blood Cancer J. 2014 Apr 11;4:e202. doi: 10.1038/bcj.2014.23. No abstract available.

21.

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.

Siegel DS, Richardson P, Dimopoulos M, Moreau P, Mitsiades C, Weber D, Houp J, Gause C, Vuocolo S, Eid J, Graef T, Anderson KC.

Blood Cancer J. 2014 Feb 21;4:e182. doi: 10.1038/bcj.2014.1.

22.

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.

O'Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, Grant B, Richards DA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Izumi R, Hamdy A, Chang BY, Graef T, Clow F, Buggy JJ, James DF, Byrd JC.

Lancet Oncol. 2014 Jan;15(1):48-58. doi: 10.1016/S1470-2045(13)70513-8. Epub 2013 Dec 10.

23.

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.

Dimopoulos M, Siegel DS, Lonial S, Qi J, Hajek R, Facon T, Rosinol L, Williams C, Blacklock H, Goldschmidt H, Hungria V, Spencer A, Palumbo A, Graef T, Eid JE, Houp J, Sun L, Vuocolo S, Anderson KC.

Lancet Oncol. 2013 Oct;14(11):1129-1140. doi: 10.1016/S1470-2045(13)70398-X. Epub 2013 Sep 19.

PMID:
24055414
24.

Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma.

Weber DM, Graef T, Hussein M, Sobecks RM, Schiller GJ, Lupinacci L, Hardwick JS, Jagannath S.

Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):319-24. doi: 10.1016/j.clml.2012.07.007.

PMID:
23040438
25.

Mutation at positively selected positions in the binding site for HLA-C shows that KIR2DL1 is a more refined but less adaptable NK cell receptor than KIR2DL3.

Hilton HG, Vago L, Older Aguilar AM, Moesta AK, Graef T, Abi-Rached L, Norman PJ, Guethlein LA, Fleischhauer K, Parham P.

J Immunol. 2012 Aug 1;189(3):1418-30. doi: 10.4049/jimmunol.1100431. Epub 2012 Jul 6.

26.

Synthesis and biological activity of simplified belactosin C analogues.

de Meijere A, Korotkov VS, Lygin AV, Larionov OV, Sokolov VV, Graef T, Es-Sayed M.

Org Biomol Chem. 2012 Aug 21;10(31):6363-74. doi: 10.1039/c2ob25586c. Epub 2012 Jun 26.

PMID:
22735304
27.

Humans differ from other hominids in lacking an activating NK cell receptor that recognizes the C1 epitope of MHC class I.

Moesta AK, Graef T, Abi-Rached L, Older Aguilar AM, Guethlein LA, Parham P.

J Immunol. 2010 Oct 1;185(7):4233-7. doi: 10.4049/jimmunol.1001951. Epub 2010 Aug 27.

28.

KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C.

Graef T, Moesta AK, Norman PJ, Abi-Rached L, Vago L, Older Aguilar AM, Gleimer M, Hammond JA, Guethlein LA, Bushnell DA, Robinson PJ, Parham P.

J Exp Med. 2009 Oct 26;206(11):2557-72. doi: 10.1084/jem.20091010.

29.

Co-evolution of KIR2DL3 with HLA-C in a human population retaining minimal essential diversity of KIR and HLA class I ligands.

Gendzekhadze K, Norman PJ, Abi-Rached L, Graef T, Moesta AK, Layrisse Z, Parham P.

Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18692-7. doi: 10.1073/pnas.0906051106. Epub 2009 Oct 16.

30.
31.

Meiotic recombination generates rich diversity in NK cell receptor genes, alleles, and haplotypes.

Norman PJ, Abi-Rached L, Gendzekhadze K, Hammond JA, Moesta AK, Sharma D, Graef T, McQueen KL, Guethlein LA, Carrington CV, Chandanayingyong D, Chang YH, Crespí C, Saruhan-Direskeneli G, Hameed K, Kamkamidze G, Koram KA, Layrisse Z, Matamoros N, Milà J, Park MH, Pitchappan RM, Ramdath DD, Shiau MY, Stephens HA, Struik S, Tyan D, Verity DH, Vaughan RW, Davis RW, Fraser PA, Riley EM, Ronaghi M, Parham P.

Genome Res. 2009 May;19(5):757-69. doi: 10.1101/gr.085738.108.

32.

Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma.

Fenk R, Michael M, Zohren F, Graef T, Czibere A, Bruns I, Neumann F, Fenk B, Haas R, Kobbe G.

Leuk Lymphoma. 2007 Dec;48(12):2345-51.

PMID:
18067009
33.

Treatment of severe hemorrhagic cystitis after allogeneic stem cell transplantation with palifermin, a recombinant human keratinocyte growth factor.

Czibere A, Bruns I, Graef T, Fenk R, Zohren F, Safaian N, Mueller M, Haas R, Kobbe G.

Biol Blood Marrow Transplant. 2007 Jul;13(7):872-4. Epub 2007 May 23. No abstract available.

34.
35.

Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase.

Diaz-Blanco E, Bruns I, Neumann F, Fischer JC, Graef T, Rosskopf M, Brors B, Pechtel S, Bork S, Koch A, Baer A, Rohr UP, Kobbe G, von Haeseler A, Gattermann N, Haas R, Kronenwett R.

Leukemia. 2007 Mar;21(3):494-504. Epub 2007 Jan 25.

PMID:
17252012
36.
37.

Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine.

Graef T, Kuendgen A, Fenk R, Zohren F, Haas R, Kobbe G.

Leuk Res. 2007 Feb;31(2):257-9. Epub 2006 Apr 18.

PMID:
16620971
38.

A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma.

Bruns I, Steidl U, Kronenwett R, Fenk R, Graef T, Rohr UP, Neumann F, Fischer J, Scheid C, Hübel K, Haas R, Kobbe G.

Transfusion. 2006 Feb;46(2):180-5.

PMID:
16441592
39.

Use of RNA interference to inhibit integrin subunit alphaV-mediated angiogenesis.

Graef T, Steidl U, Nedbal W, Rohr U, Fenk R, Haas R, Kronenwett R.

Angiogenesis. 2005;8(4):361-72. Epub 2006 Jan 7.

PMID:
16400518
40.

Distinct gene expression pattern of malignant hematopoietic stem and progenitor cells in polycythemia vera.

Steidl U, Schroeder T, Steidl C, Kobbe G, Graef T, Bork S, Pechtel S, Kliszewski S, Kuendgen A, Rohr UP, Fenk R, Schroeder M, Haase D, Haas R, Kronenwett R.

Ann N Y Acad Sci. 2005 Jun;1044:94-108. Review.

PMID:
15958702
41.

Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings.

Neumann F, Graef T, Tapprich C, Vaupel M, Steidl U, Germing U, Fenk R, Hinke A, Haas R, Kobbe G.

Bone Marrow Transplant. 2005 Jun;35(11):1089-93.

PMID:
15821769
42.

Transplantation of allogeneic CD34+-selected cells followed by early T-cell add-backs: favorable results in acute and chronic myeloid leukemia.

Kobbe G, Fenk R, Neumann F, Bernhardt A, Steidl U, Kondakci M, Graef T, Aivado M, Vaupel M, Huenerlituerkoglu AN, Kronenwett R, Pape H, Hildebrand B, Germing U, Haas R.

Cytotherapy. 2004;6(6):533-42.

PMID:
15764020
43.

Single-agent thalidomide for treatment of first relapse following high-dose chemotherapy in patients with multiple myeloma.

Fenk R, Hoyer B, Steidl U, Kondakci M, Graef T, Heuk R, Ruf L, Strupp C, Neumann F, Rohr UP, Hildebrandt B, Haas R, Kobbe G.

Leukemia. 2005 Jan;19(1):156-9. No abstract available.

PMID:
15510204

Supplemental Content

Support Center